N Govindarajan, Managing Director of Aurobindo Pharma, at the company#39;s earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.Aurobindo Pharma, Vaxxinity seek DCGI nod to begin Phase-2/3 of COVID-19 jab UB-612
N Govindarajan, Managing Director of Aurobindo Pharma, at the company#39;s earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment